

AUDITING OF WORKING-ACCOUNTS AND BALANCE  
FOR THE FINANCIAL YEAR 2014  
OF THE "EUROPEAN LIVER PATIENTS ASSOCIATION"

As appointed Accountant, I checked the annual accounts of the year 2014 of the European Liver Patients Associations (ELPA).

The financial statements for the year 2014 are drawn up in Euro.

The bookkeeping was established in accordance with Belgian legislation and accounting standards. The bookkeeping is held on a cash-basis. All the documents I verified enabled me to match every receipt and expenditure to a supporting document.

The financial year closes at a profit brought forward of 517.133,12 Euro. The profit of the year 2014 amounts to 214.305,70 Euro and the balance-total to 622.867,56 Euro.

It is my opinion that the balance sheet and the profit and loss account as at 31 December 2014 gives a fair view of the financial situation of the organisation.

Brussels, 20th April 2015

Sara CEUSTERS

Accountant



**Sara CEUSTERS**  
*Accountant - belastingconsulent*

BVBA ICOUNT4U  
Reper-Vrevenstraat 137  
1020 BRUSSEL  
Tel. 02 646 66 61  
Fax 02 649 38 00

<b>ASSETS</b>	<b>2014</b>	<b>2013</b>	<b>2012</b>
<b>III. TANGIBLE FIXED ASSETS</b>	<b>1.896,21</b>	<b>1.323,63</b>	<b>1.536,86</b>
<b>VII. AMOUNTS RECEIVABLE WITHIN ONE YEAR</b>	<b>239.713,07</b>	<b>7.779,90</b>	<b>25.793,97</b>
<b>IX. CASH AT BANK AND IN HAND</b>	<b>349.422,59</b>	<b>371.618,65</b>	<b>118.280,41</b>
<b>X. DEFERRED CHARGES AND ACCRUED INCOME</b>	<b>31.835,69</b>	<b>1.303,90</b>	<b>298,21</b>
<b>TOTAL ASSETS</b>	<b>622.867,56</b>	<b>382.026,08</b>	<b>145.909,45</b>

<b>LIABILITIES</b>	<b>2014</b>	<b>2013</b>	<b>2012</b>
<b>V. BROUGHT FORWARD RESULT</b>	<b>517.133,12</b>	<b>302.827,42</b>	<b>121.230,75</b>
<b>IX. DEBTS ON LESS THAN ONE YEAR</b>	<b>105.734,44</b>	<b>79.198,66</b>	<b>24.678,70</b>
<b>TOTAL LIABILITIES</b>	<b>622.867,56</b>	<b>382.026,08</b>	<b>145.909,45</b>

	<b>2014</b>	<b>2013</b>	<b>2012</b>
<b>CORPORATE REVENUES</b>	<b>1.007.745,50</b>	<b>1.042.988,04</b>	<b>951.449,03</b>
<b>CORPORATE COSTS</b>	<b>792.298,74</b>	<b>858.929,96</b>	<b>921.878,07</b>
<i>Consommables</i>	598.627,70	700.978,38	671.218,51
Policy and Advocacy	355.892,28	320.481,92	109.749,22
General meeting	55.976,96	66.362,35	66.048,10
Meeting Stearing Committee	27.012,43	25.223,10	468,95
World Hepatitis day		41.725,56	44.379,07
AD Board Meeting	72.209,76	55.464,02	83.614,61
Euro Hepatitis Care Index			332.030,82
AASLD	14.172,79	9.687,17	11.388,66
Fundraising			4.924,97
Policy Meetings		33.418,07	5.665,11
Scientific Work	24.298,48	15.609,77	12.949,00
Blueprintproject		31.801,42	
White paper project	49.065,00	101.205,00	
<i>Various Goods and Services</i>	191.967,04	157.006,43	248.621,05
<i>Depriciations</i>	1.704,00	945,15	2.038,51
<b>RESULT OF ACTIVITY</b>	<b>215.446,76</b>	<b>184.058,08</b>	<b>29.570,96</b>

	<u>2014</u>	<u>2013</u>	<u>2012</u>
<b>FINANCIAL COSTS</b>	<b>(1.533.73)</b>	<b>(2.831.90)</b>	<b>(2.329.07)</b>
<b>FINANCIAL INCOME</b>	<b>392.67</b>	<b>370.49</b>	<b>298.21</b>
<b>RESULT OF THE YEAR BEFORE TAXES</b>	<b>214.305.70</b>	<b>181.596.67</b>	<b>27.540.10</b>
<b>RESULT OF THE YEAR</b>	<b>214.305,70</b>	<b>181.596,67</b>	<b>27.540,10</b>



## Funding sources 2014

Industry <sup>1</sup> related income		
Name of company / funder	Amount of income <sup>2</sup>	Percentage of overall budget
AbbVie Europe	€ 80.000	7,94 %
AbbVie Global	€ 175.000	17,37 %
Bayer	€ 150.000	14,88 %
BMS	€ 96.000	9,53 %
Gilead Sciences	€ 205.950	20,44 %
F.Hoffman-La Roche	€ 41.000	4,07 %
Janssen Pharmaceutical	€ 90.000	8,93 %
Lundbeck	€ 80.000	7,94 %
MSD	€ 75.000	7,44 %
Sirtex	€ 2.000	0,20 %
<b>Subtotal:</b>	<b>€ 994.950</b>	<b>98,73 %</b>
Non-industry related income		
Source of funding <sup>3</sup>	Amount of income	Percentage of overall budget
Membership fees	€ 2.800	0,28 %
Miscellaneous	€ 9.995,50	0,99 %
<b>Subtotal:</b>	<b>€ 12.975,50</b>	<b>1,27 %</b>
<b>TOTAL:</b>	<b>€ 1.007.745,50</b>	

<sup>1</sup> Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

<sup>2</sup> This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

<sup>3</sup> e.g. membership fees, donation